+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Glioma Therapeutics Market 2019-2023 - Product Image

Global Glioma Therapeutics Market 2019-2023

  • ID: 4721496
  • Report
  • December 2018
  • Region: Global
  • 114 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Mylan
  • NextSource Biotechnology
  • Novartis
  • MORE
Strategic alliances to drive growth in the market. Pharmaceutical companies are collaborating to develop medications for the treatment of glioma. These alliances can enhance R&D activities for new drugs for the treatment of glioma. The analysts have predicted that the glioma therapeutics market will register a CAGR of more than 9% by 2023.

Market Overview

Expected approval of late-stage pipeline molecules

As the market is currently experiencing an acute lack of approved therapies, these late-stage pipeline molecules can tap into this unmet demand from the glioma patient pool. Once these molecules are launched during the forecast period, the global glioma therapeutics market should observe strong value growth from these newly launched therapeutics.

Availability of alternative therapies

Despite the availability of medications for the treatment of the glioma, there are several alternative procedures. The high cost, side effects, and long duration of treatment with the available medications are increasing patients’ inclination toward the surgical and radiation treatment options.

For the detailed list of factors that will drive and challenge the growth of the glioma therapeutics market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including NextSource Biotechnology and Novartis, the competitive environment is quite intense. Factors such as the expected approval of late-stage pipeline molecules and the strategic alliances, will provide considerable growth opportunities to glioma therapeutics manufactures. F. Hoffmann-La Roche, Merck Sharp & Dohme, Mylan, NextSource Biotechnology, and Novartis are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Mylan
  • NextSource Biotechnology
  • Novartis
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Small molecules - Market size and forecast 2018-2023
  • Biologics - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 12: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Mylan
  • NextSource Biotechnology
  • Novartis
PART 13: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Segments of global oncology therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in Americas
Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in APAC
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Decision framework
Exhibit 40: Some of the therapeutics that received orphan drug designation from the US FDA are mentioned below
Exhibit 41: Impact of drivers and challenges
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: F. Hoffmann-La Roche - Vendor overview
Exhibit 48: F. Hoffmann-La Roche - Business segments
Exhibit 49: F. Hoffmann-La Roche - Organizational developments
Exhibit 50: F. Hoffmann-La Roche - Geographic focus
Exhibit 51: F. Hoffmann-La Roche - Segment focus
Exhibit 52: F. Hoffmann-La Roche - Key offerings
Exhibit 53: F. Hoffmann-La Roche - Key customers
Exhibit 54: Merck Sharp & Dohme - Vendor overview
Exhibit 55: Merck Sharp & Dohme - Business segments
Exhibit 56: Merck Sharp & Dohme - Organizational developments
Exhibit 57: Merck Sharp & Dohme - Geographic focus
Exhibit 58: Merck Sharp & Dohme - Segment focus
Exhibit 59: Merck Sharp & Dohme - Key offerings
Exhibit 60: Merck Sharp & Dohme - Key customers
Exhibit 61: Mylan - Vendor overview
Exhibit 62: Mylan - Business segments
Exhibit 63: Mylan - Organizational developments
Exhibit 64: Mylan - Geographic focus
Exhibit 65: Mylan - Key offerings
Exhibit 66: Mylan - Key customers
Exhibit 67: NextSource Biotechnology - Vendor overview
Exhibit 68: NextSource Biotechnology - Organizational developments
Exhibit 69: NextSource Biotechnology - Key offerings
Exhibit 70: NextSource Biotechnology - Key customers
Exhibit 71: Novartis - Vendor overview
Exhibit 72: Novartis - Business segments
Exhibit 73: Novartis - Organizational developments
Exhibit 74: Novartis - Geographic focus
Exhibit 75: Novartis - Segment focus
Exhibit 76: Novartis - Key offerings
Exhibit 77: Novartis - Key customers
Exhibit 78: Validation techniques employed for market sizing
Exhibit 79: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Mylan
  • NextSource Biotechnology
  • Novartis
  • MORE
Global glioma therapeutics Market 2019-2023

The analyst recognizes the following companies as the key players in the global glioma therapeutics market: F. Hoffmann-La Roche, Merck Sharp & Dohme, Mylan, NextSource Biotechnology, and Novartis.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the strategic alliances.”

According to the report, one of the major drivers for this market is the expected approval of late-stage pipeline molecules.

Further, the report states that one of the major factors hindering the growth of this market is the availability of alternative therapies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Mylan
  • NextSource Biotechnology
  • Novartis
Note: Product cover images may vary from those shown
Adroll
adroll